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Abstrm:t To design optimal strategies for intraceHular delivery 
of autisense phosphorotidoate oHgonudeotides, it may be useful 
to understand their Interaction with cellular macromolecules. Nu- 
clear extracts from LOX amelonotlc myelom cells were studied 
for protein bindinll to idtoapborothioate oli8onucleotides u ing a 
Southweetern protocol. Multiple nuclear proteins bound to the 
pboepborotldonte ollaonucleotides but no detectable protein bind- 
In8 was found to phosphodleatev oligonucleotides. The protein 
with the strongest binding sisnals was shown by immunopreciplta- 
tion to be nucleolar C23/nucleolln, a II0 kDa protein. With 
glutathlone S.transferoae/nucleolln fusion protein constructs, the 
region of nucleolln containing the RNA recognition motifs had 
binding activity to phosphorothioate oligonucleotides. 
Key words: Phosphorothioate oligonucleotide; C23/nucleolin; 
RNA recognition motif 
I, Introduction 
Antisense oligonucleotides have been shown to inhibit gene 
expression in a variety of in vitro systems [I-5]. Design of 
optimal strategies for delivery of antisense oligonucleotides re- 
quires an understanding of the mechanisms of internalization 
into cells and their subcellular localization. Studies have shown 
that internalization of some antisense oligonucleotides occurs 
by pinocytosis, which involves a 75-80 kDa membrane r ceptor 
protein [6=8], Other studies have explored the intracellular t af- 
ticking and the intracellular macromolecules towhich antisense 
olig~nucleotides bind. Some antisense oligonucleotides were 
shown to accumulate in nuclei [8-13] and bind to nuclear pro. 
reins [8,10,14], but no specific nuclear binding protein was 
found, 
Phosphorothioate oli8onucleotides are being evaluated as 
inhibitors of gene expression: they have the advantage of 
greater stability than phosphodiester oligonucleotides because 
of their greater esistance to nucleases [15]. Stein et al. [15] 
reported one to two order of magnitude increased non-se- 
quence-specific protein binding by phosphorothioate oligonu- 
deotides as compared to phosphodiester oligonucleotides. 
Such interactions could cause non-sequence-specific biological 
effects, and may affect he subcellular localization and the an- 
tisense activity of phosphorothioate oligonucleotides. 
Using nuclear protein extracts from human LOX amelanotic 
myeloma culture cells and an in vitro Southwest protein bind- 
ing assay, we have demonstrated several nuclear proteins 
*Corresponding author. Fax: (I) (713) 798 3145. 
Abbreviations: GST, glutathione S-transferase; RRM, RNA recogni- 
tion motif. 
bound phosphorothioate oligonucleotides in a non-sequence 
specific manner. These proteins did not bind phosphodiester 
oligonucleotides. The protein with the highest binding signal to 
phosphorothioate oligonucleotides has been identified by im- 
munoprecipitation as C23/nucleolin. Using bacterially ex- 
pressed recombinant glutathione S-transferase/nucleolin fusion 
proteins, binding of phosphorothioate oligonucleotides to nu- 
cleolin was localized to the carboxy half of the protein, the 
region which contains the RNA recognition motifs of nucleolin. 
:2. Materials and methods 
2.1. Antisense oligonucleotides 
Synthesis ofantisense phosphorothioate oligonucleotides to the p120 
gene sequence has been previously described [16]. The sequences are: 
ISIS 3466-CACCCGCCTTGGCCTCCCAC; ISIS 3790-GTGGGAG- 
GCCAAGGCGGGTG; ISIS 3460-CCCCATGGTACTGTGGCA- 
GG; ISIS 3462-CCTTCCTCCCGCTGAGCCCC; ISIS 3789-CACG. 
CCTCCCGACTCTGCCC. 
BV-102 (phosphodiester analog of ISIS 3466), phosphodiester 
ologonucleotides BV-90 (AGGAGACTTATTTGGCTTAGG) and 
BV-96 (CATGGGGCGCAAGTTCAATCC) were synthesized bythe 
Del~'trtment of Cell Biology, Baylor College of Medicine. RE7, a ran- 
dom sequence phosphorothioate oligonucleotide with sequence TAT- 
TACGTACTAGATTCTAC has been previously described [17]. 
2.2. Cell lines 
Human amelanotic melanoma cells (LOX), provided by Dr. D.J. 
Dykes, (Southern Reseach Institute, Birmingham, AL) were subcul- 
tured in RPMI-1640 medium, supplemented with 10% fetal bovine 
serum and I% penicillin-streptomycin liquid (Gibco BRL). 
2.3. Preparation of nuclear and cytoplasmic extract 
LOX nuclear and cytoplasmic protein extracts were prepared essen- 
tially as described by Dignam et al. [18]. Protein concentration was 
determined by the Bradford assay. 
2.4. SDS.PAGE, Southwestern. a d Western blot analysis 
Protein extracts were lectrophoresed on SDS-polyacrylamide gels as 
described by Laemmli [19], and proteins transferred tonitrocellulose 
electrophoretically t 100 V for one hour in transfer buffer (192 mM 
glycine, 25 mM Tris-HCl, 20% (v/v) methanol). Southwestern a alysis 
was modified from Miskimins et al. [20]. Blots were blocked in 5% 
nonfat dry milk in 10 mM HEPES, pH 7.9, for at least one hour. 
Binding to radiolabeled phosphorothioate oligonucleotides was per- 
formed in binding buffer (10 mM HEPES, pH 8.0, 50 mM NaCI, 10 
mM MgCI,, 0.1 mM EDTA, I mM dithiothreitol, 0.25% nonfat dry 
milk, 5,ug/mi poly i/poly C) containing I x l0 s CPM/ml of3'P oligonu. 
cleotide labeled at the 5' end with [7-32p]ATP and T4 polynucleotide 
kinase. Binding was done for a minimum of 1.5 h at room temperature. 
The blots were washed for 2 h in 2 changes of wash buffer (same as 
binding buffer including 0.3 M NaCI and without poly I/poly C or 
labeled oligonucleotide). The blot was covered with plastic wrap and 
exposed to autoradiography using an intensifying screen at -70 o C. 
For Western analysis, blots were blocked in 5% nonfat dry milk in 
10 mM HEPES, pH 7.9. Binding to anti-C23 monocional ntibody 
MS3 [21] was done at a 1:400 dilution of ascites in TBST buffer (50 
mM Tris-HCI, pH 8, 150 mM NaCI, 0.05% Tween-20) for 2 h followed 
by three washes of 5 min in TBST. Binding to alkaline phosphatase- 
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Fig. 1. Detection of phosphorothioate oligonucleotide binding to LOX 
cell nuclear and cytoplasmic protein extracts.LOX cell nuclear extracts 
from two independent preparations (lanes 2-3 and 5-6) and cytoplas- 
mic extract (lanes 1 and 4) were separated on a 4-15% SDS poly- 
acrylamide gradient gel and transferred to nitrocellulose filters. The 
filters were incubated with 5'.3"~P.labeled ISIS 3790 (lanes 1-3) or ISIS 
3466 (lanes 4-6) as described insection 2, and exposed to autoradiogra. 
phy. The position of prestained molecular mass markers for the South- 
west blots are indicated to the right. The left three lanes how Coomas- 
sic blue staining of the protein extracts: M, molecular weight markers; 
N, nuclear extract; C, cytoplasmic extract. 
conjugated secondary antibody (goat anti-mouse IgG from Promega) 
was done for ! h followed by 3 washes in TBST. Color development 
was done with alkaline phosphatase r agents according to the Promega 
protocol. 
2.5. Immunoprecipitation of uc/eolin 
LOX nuclear extract (50 ,ug) was precleared with Protein G Plus/ 
Protein A agarose affinity beads (Oncogene Science) in IP buffer (10 
mM Tris HCI (pH 8.0), 10 mM KCI, 0.5 mM MgCI2 containing ! ,ug/ml 
each leupeptin, pepstatin, and aprotinin) for one h at 4°C, and then 
precipitated with anti-nucleolin monoclonai ntibody MS3 (20gg puri- 
fied IgG), overnight at 40C in the same buffer. The precipitated com- 
plexes were tumbled with Protein G Plus/Protein A agarose beads for 
6 h at 40C, and washed three times in IP buffer. The washed beads 
containing the precipitated complexes were resuspended in SDS gel 
loading buffer (100 mM Tris-HCl, pH 6.8, 0.2 M dithiothreitol, 4% 
SDS, 20% glycerol), boiled for five min, and electrophoresed on 4-15% 
polyacrylamide g ls. Transfer to nitrocellulose and binding to radiola- 
beled oligonucleotides were as described above. 
2.6. Construction ofnucleolin deletion mutants 
All deletion mutants were constructed and expressed as glutathione 
S-transferase (GST) fusion proteins in DH5alpha E. coil cells. Plasmid 
pMAMC23, a pMAMneo construct (Clontech) containing the human 
nucleolin eDNA [22], was digested with Mscl and Xhol and treated with 
Klenow fragment of DNA polymerase I. The nucleolin eDNA fragment 
was agarose-gel purified using the QIAquick gel extraction kit (Qiagen) 
1 2 3 4 5 
and ligated with blunt-ended EcoRl-digested pGEX 3X vector (Pharo 
macia) which resulted to clone pGC23/Y. The orientation ofthe insert 
was checked by BamHI and NcoI digestion. DNA sequencing was done 
to confirm if nucleolin eDNA was in frame with the GST sequence. 
Deletion from the Y end of nucleolin was done by Ncol digestion of 
pGC23/Y and filling in the 5' protruding end with alpha-phospho- 
rothioate nucleotides and Klenow fragment of DNA polymerase I. The 
DNA was then digested with HindIII and 3' to 5' deletion was done 
using Erase-a-Base kit (Promega). 
A similar procedure was done for 5' deletion. Plasmid pGC23/Y was 
linearized with BamHI and the 5' protruding end was protected. The 
linearized plasmid was digested with Sinai prior to ExoIII digestion 
using Erase-a-Base kit. All deletion mutants were sequenced using the 
Sequenase kit (Anl~.,'~ham Life Science). 
The GST-pI20 cn-.sttuct (pG116) was prepared as described previ- 
ously [23]. 
2. 7. Expression and purification of GST fusion proteins 
An overnight 5.0 ml Luria broth culture was added into 50 ml Luria 
broth with 100,ug/ml ampicillin. After i h of shaking at 37°C, expres- 
sion was induced with 0.5 mM IPTG for 3 h. The E. coli cells were 
pelleted and resuspended in 5 ml NETN buffer (20 mM Tris-HCI, pH 
8.0, 100 mM NaCI, ! mM EDTA, 0.5% NP-40, 0.1 mM PMSF, 0.25 
mg/ml N-tcsyl-phenylalanyl-chloromethyl k tone). The cells were lysed 
by mild sonication on ice and centrifuged at 12,000 × g for 20 min at 
4°C. The supernatant was tumbled for 30 rain at 4°C with 0.15 ml of 
glutathione-Sepharose 4B (Pharmacia) which had been previously 
washed three times and resuspended (50% resin) in NETN buffer. The 
slurry was centrifuged at 500 x g for 5 min at 4°C and the pellet was 
washed 3 times with NETN buffer. The resin was boiled for 5 rain in 
0.15 ml sample buffer (0.126 mM Tris-HCI, pH 6.8, 20% glycerol, 2% 
SDS, 2% 2-mercaptoethanol, 0.001% Bromophenol b ue) prior to gel 
electrophoresis. 
3. Results 
3.1. Phosphorothioate oligonucleotides bind efficiently to a 110 
kDa nuclear protein from LOX cells in a non-sequence 
specific manner 
Several phosphorothioate oligonucleotides which were syn- 
thesized as antisense oligonucleotides to the gene encoding 
p120 protein [16], a human proliferation-associated nucleolar 
antigen, were assayed for LOX nuclear protein binding by a 
Southwestern method. As shown in Fig. !, strong binding to 
an approximately 110 kDa protein was detected with phospho- 
rothioate oligonucleotides ISIS 3466 and its complementary 
sequence ISIS 3790. Minor binding was also observed to four 
25-50 kDa proteins. Other phosphorothioate oligonucleotides, 
including ISIS 3460, ISIS 3462, ISIS 3789, and RE7, (see sec- 
tion 2) showed similar strong binding to a !10 kDa nuclear 
prot,:in, which was the most dense band detected for all phos- 
phorothioate oligonucleotides tested (data not shown). The 
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Fig. 2. Competition with unlabeled oligonucleotides: 5'.32p.labeled ISIS 3466 (I pmol) was incubated with nitrocellulose filters containing LOX cell 
nuclear extract as described in A. The following unlabeled competitor oligonucleotides were included in the incubation: Lane l-none; lane 2- 
phosphodiester oligonucleotide BV 102, 100 pmol; lane 3- BV 102, 1,000 pmol; lane 4- phosphodiester oligonucleotide BV 90, 1,000 pmol; lane 5- 
phosphodiester oligonucleotide BV 96, 1,000 pmol; lane 6, phosphorothioate oligonucleotide RE7, 10 pmol; lane 7, RE7, 100 pmol; lane 8, RE7, 
1,000 pmol; lane 9, phosphorothioate oligonucleotide ISIS 3466, 100 pmol; lane 10, phosphorothioate oligonucleotide ISIS 3462, 100 pmol, 
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Fig. 3. Competition with polysaccharides. 5"~2p-labeled ISiS 3466 (1 
pmol) was incubated with nitrocellulose filters containing LOX cell 
nuclear extract, The following polysacchaHdes or oligonucleotide w re 
tested for competition with binding of ISIS 3466, all at 1,000 pmol 
( 1,000-fold molar excess): lane 1, no added competitor; lane 2, dextran 
(mol.wt. 70,000); lane 3, dextran sulfate (mol.wt. 8,000); lane 4, pento- 
san polysulfate (mol.wt. 3,000); lane 5, unlabeled ISIS 3466. 
II0 kDa phosphorothioate oligonucleotide-binding protein 
was also detected in the cytoplasmic fraction, but at a much 
lower level in comparison to the nuclear fraction (Fig. i). No 
LOX cell nuclear protein binding was detected using 32P-la- 
beled phosphodiester oligonucleotide BV-102, which is homol- 
ogous to ISIS 3466 (data not shown). 
To verify that the binding to the 110 kDa protein was se- 
quence non-specific and was depeadent on the presence of 
phosphorothioate in the oligonucleotide, competition studies 
were performed. Using ~'P-labeled phosphorothioate oligonu- 
cleotide ISIS 3466 and various unlabeled competing oligonucle- 
otides, all phosphorothioate oligonucleotides tested (ISIS 3466, 
ISIS 3462, and RE7) efficiently competed with the binding of 
the labeled phosphorothioate oligonucleotide to the 110 kDa 
protein (Fig. 2, lanes 6--10). The phosphodiester oligonucleo- 
tides tested (BV-102, BV-90, and BV-96) did not compete with 
the binding by ISIS 3466 to the 110 kDa protein (lanes 2--5), 
No degradation of either phosphodiester or phosphorothioate 
oligonucleotides during the competition binding reaction was 
detected, by polyacrylamide gel electrophoresis (data not 
shown). Accordingly, phosphorothioate oligonucleotides but 
not phosphodiester oligonucleotides bind predominantly tothe 
il0 kDa protein, 
Phosp~orothioate oli8onucleotides are polyanionic com- 
pounds, Some proteins have a general affinity for polyanionic 
compounds, uch as that ofthe human immunodeficiency virus 
protein gpl20, whose V3 loop binds sulfated polysaccharides 
as well as phosphorothioate oligonucleotides [24]. To test if 
other polyanionic ompounds competed with binding of the 
phosphorothioate oligonucleotide ISIS 3466 to nuclear pro- 
teins detected in the Southwestern assay, dextran sulfate, pen- 
tosan polysuifate, or unsulfated extran (nonanionic polymer 
control) were used, At a 1,000-fold molar excess these polysac- 
charities were unable to compete with binding of ISIS 3466 to 
the nuclear proteins (Fig, 3, lanes 2-4), A 1,000-fold excess 
unlabeled ISIS 3466 completely competed with the binding of 
radiolabeled 3466 (lane 5), The binding of phosphorothioate 
oli8onucicotides to these nucle:zr proteins is clearly not the 
result of general binding to polyanions, 
3.2. The !10 kDa phosphorothioate oligonucleotide binding 
protein is nucleolin 
By Southwestern analysis, the I l0 kDa phosphorothioate 
oligonucleotide binding protein was enriched in nucleolar ex- 
tracts (data not shown). To identify nuclcolar proteins which 
comigrated with the 110 kDa oligonucleot~de binding protein, 
monoclonal antibodies to nucleolar proteins were used. The 
110 kDa phosphorothioate oligonucleotide binding protein 
comigrated precisely with C23/nucleolin, as detected by West- 
ern blot analysis (see Fig. 4, lanes I and 4). To determine if the 
110 kDa phosphorothioate oligonucleotide biading protein was 
C23/nucleolin, it was immunoprecipitated from LOX nuclear 
extracts by anti C23/nucleolin antibodies. Western blot analysis 
confirmed that the immunoprecipitated protein was in fact nu- 
cleolin (Fig, 4, lower panel). The immunopre.~ipitated C23/ 
nucleolin bound to 32P-labeled phosphorothioa~te oligonucleo- 
tides ISIS 3466 and ISIS 3790, (Fig. 4, upper panel). 
3.3. Localization o f t  he nucleolin phosphorothioate 
oligonucleotide binding region 
To determine the regions of nucleolin that bound to the 
phosphorothioate oligonucleotides, various fragments of nucle- 
olin eDNA were fused with the glutathione S-transferase g ne. 
The fusion proteins were purified from E. col/, and South- 
Southwestern Blot 
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Fig. 4. Phosphorothioate.oligonucleotide binding to immunoprecipi. 
tated nucleolin.Nucleolin was immunoprecipitated from LOX nuclear 
extracts as described insection 2. Protein fractions were electrophore- 
sed on 4--15% SDS polyacrylamide gradient gels, transfered tonitrocel- 
lulose, and incubated with 5°-3'P-labeled ISIS 3466 (lanes 1-3) or ISIS 
3790 (lanes 4-6). Lanes I and 4, untreated LOX nuclear extracts; lanes 
2 and 5, supernatant from LOX nuclear extracts immunoprecipitated 
with nucleolin monoclonal ntibody MS3; lanes 3 and 6, precipitate 
from LOX nuclear extracts immunoprecipitated with nucleolin mono- 
clonal antibody MS3. NIn, nucleolin; IgG-H, immunoglobulin G,
heavy chain; IgG-L, immunoglobulin G, light chain. 
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B. Binding Assay 
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western analysis was done with ~2P-labeled ISIS 3466 or ISIS 
3790. No binding of either phosphorothioate oligonucleotide 
to a control fusion protein GST/pI20 was detected (Fig. 5, lane 
9). Binding was observed for GST/nucleolin fusion proteins 
containing nucleolin sequences 286-539, 286-627, 286-707, 
353- 707, 394-707, and 423-707 (Fig. 5, lanes 3-8). No binding 
was detected to nucleolin fragments containing sequences from 
Fig. 5. Glutathione S-transferase/nucleolin fus on proteins (A) and their 
binding to phosphorothioate oligonucleotides (B).The fusion proteins 
were prepared and purified as described in section 2. Approximately 
equal amount of fusion proteins, as determined by Coomassie blue 
staining, were lectrophoresed, transferred tonitrocellulose, and bound 
with 2 pmol of 32P-labeled ISIS 3466 (upper panel) or ISIS 3790 (middle 
panel). The open rectangles (clones 1-8) represent the nucleolin se- 
quence with numbers indicating the positions of amino acid residues 
and broken lines represent the deleted nucleolin sequences. Each 
hatched box represents the 1 l-amino acid consensus sequence for RNA 
recognition. Clone 9 is a fusion of GST and amino acids 1-110 of 
nucleolar protein p120. Lane numbers in (B) correspond toclone num- 
bers in (A). 
6-  
286-411 or 286 4A9 (Fig. 5, lanes 1 and 2; both contain amino 
acids 627-707). Coomassie staining showed that similar 
amounts of fusion proteins were loaded in each lane (Fig. 5, 
lower panel). The region of C23/nucleolin which bound phos- 
phorothioate oligonueleotides in this assay contains the RNA 
recognition motifs (RRM) of nucleolin. The shortest C231nu- 
cleolin fragments to which binding of phosphorothioate ol-
igonucleotides was detected (286-539 and 423-707) contain 
three l l-amino acid RRMs (domains A-C and B-D, respec- 
tively); the fragments containing only RRM A or A and B 
(286-411 and 286-449, respectively) did not bind phospho- 
rothioate oligonucleotides. Studies are currently in progress to 
determine precisely the minimal region required for oligonucle- 
otide binding and the relative contribution of each RRM. 
4. Discussion 
Studies that explored the internalization and subceilular lo- 
calization of oligonucleotides demonstrated that both 
phosphodiester and phosphorothioate oligonucleotides accu- 
mulate predominantly in the cell nucleus [8-13]. Previous in 
vitro binding of phosphorothioate oligonucleotides to nuclear 
proteins has been demonstrated [8,10,14], but specific proteins 
were not identified. The present study shows non sequence- 
specific in vitro binding of phosphorothioate oligonucleotides 
to nuclear proteins isolated from human LOX cells; very low 
level binding was found for cytoplasmic proteins. This binding 
was dependent on the presence of the phosphorothioate back- 
bone. Only phosphorothioate oligonucleotides but not 
phosphodiester oligonucleotides competed with the binding of 
radiolabeled phosphorothioate oligonucleotides. 
A i 10 kDa protein which had consistently strong phospho- 
rothioate oligonucleotide binding signal was shown by im- 
munoprecipitation to be C23/nucleolin. Binding to nucleolin 
was also confirmed using recombinant glutathione S-trans- 
ferase/nucleolin fusion proteins. Nucleolin is a predominantly 
nucleolar protein which is associated with nucleolar chromatin 
in interphase and with NOR (nucleolar organizing regions) 
during mitosis [25,26]; it has been suggested to play a role in 
preribosome assembly [27]. C23/nucleolin may also function as 
a transcriptional repressor [28], a nucleus to cytoplasm shuttle 
protein [29], and a nuclear matrix attachment region protein 
[30]. 
C23/nucleolin has been demonstrated to bind RNA, with its 
RNA recognition motifs [31] as well as single stranded DNA 
[32-34]. Using GST/nucleolin constructs, we have shown that 
three RNA recognition motifs appear to be necessary for phos- 
phorothioate oligonucleotide binding activity. The glycine- 
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~- ine- r i ch  (GAR) region at the carboxy terminus of C23/ 
nucleolin may facilitate its binding to phosphorothioate ol-
igonucleotides (compare amino acids 286-707 and 286-627 in 
Fig. 5). This GAR region has been shown to be essential for 
efficient binding of C23/nucleolin to RNA [34,35]. 
Binding of phosphorothioate oligonucleotides to C23/nucle- 
olin and other nuclear proteins may relate to their effects on 
cell function. A strong binding to a nucleolar protein could 
potentially be toxic to normal cells by affecting their growth 
and reproduction. For example, binding of phosphorothioate 
oligonucleotides to C23/nucleolin could inhibit its function in 
ribosomal RNA synthesis, resulting in severe toxicity. Such 
binding to nuclear proteins could be involved in some of the 
random effects noted for phosphorothioate oligonucleotides 
(reviewed in Stein and Cheng [5]). Studies on these ffects need 
to be developed. 
Several other phosphorothioate oligonucleotide binding pro- 
teins have been previously identified, An 80 kDa membrane 
protein isolated from CHO fibroblasts and HL-60 cells [6,7] 
was found to bind to both phosphorothioate and phosphod. 
Jester oligonucleotides, This binding was competed by other 
polyanions, including dextran sulfate and pentosan polysulfate. 
Other phosphorothioate and phosphodiester bindin~ proteins 
are recombinant soluble CD4, the T-cell surface receptor for 
the human immunodeficiency virus-I envelope glycoprotein 
8pl20 [36], gpl20 [24] and protein kinase C, beta-I isoform [37]. 
Binding of phosphorothioate oligonucleotides to gpl20 was 
demonstrated to occur at the positively charged v3 loop do- 
main, and was specific for phosphorothioate oligonucleotides; 
no binding was detected for phosphodiester oligonucleotides 
[24]. This result was similar to our finding with C23/nucleolin 
and other nuclear proteins. However, the v3 loop domain inter- 
acted with sulfated polysa~harides. Our data showed that the 
sulfated polysa~harides dextran sulfate and pentosan polysul- 
fate did not compete with the binding of phosphorothioate 
oligonucleotides to C23/nucleolin, which indicates a different 
type of interaction than by simple ~tionic-anionic binding. 
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